Health Care Distributors

NPGC

NPGC released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 13.84 B, actual EPS CNY 0.12

NPGC FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

NPGC released FY2025 Q4 earnings on April 10 After-Market (BJT), actual revenue CNY 13.83 B, actual EPS CNY 0.1428

NPGC released FY2025 annual earnings on April 10 After-Market BJT, actual revenue CNY 54.96 B, actual EPS CNY 0.426

NPC FY2025 Annual Earnings Release Scheduled for April 11, 2026 After-Market BJT

NPC released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 13.17 B, actual EPS CNY 0.0785

NPC released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 40.87 B, actual EPS CNY 0.2509

NPC FY2025 Q3 Earnings Release on October 31 Pre-Market BJT

Guangzhou Pharmaceutical Acquires 11.04% of Nanjing Pharmaceutical

NPC released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 27.97 B, actual EPS CNY 0.201

NPC released FY2025 Q1 earnings on August 29 After-Market (BJT), actual revenue CNY 14.25 B, actual EPS CNY 0.135

NPC released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 13.98 B, actual EPS CNY 0.1005

NPC to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Nanjing Pharmaceutical's ESG Rating Improved to BB

NPC FY2025 Q1 Earnings Release Scheduled for April 30 After-Market BJT

NPC released FY2024 earnings on April 10 After-Market (BJT), actual revenue CNY 53.7 B, actual EPS CNY 0.438

NPC released FY2024 Q4 earnings on April 10 After-Market (BJT), actual revenue CNY 12.76 B, actual EPS CNY 0.0981

NPC FY2024 Annual Earnings Release Scheduled for April 10, 2025, After-Market BJT

Nanjing Pharmaceutical Receives 110 Million Yuan Loan Support for Stock Buyback from Industrial Bank

NPC released FY2024 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 13.71 B, actual EPS CNY 0.1

600713

According to the Zhitong Finance APP, NPC disclosed its third-quarter report for 2025. The company achieved a revenue of 41.135 billion yuan in the first three quarters, a year-on-year increase of 0.48%; the net profit attributable to shareholders was 402 million yuan, a year-on-year decrease of 9.03%; the net profit excluding non-recurring gains and losses was 371 million yuan, a year-on-year decrease of 14.78%; the basic earnings per share were 0.31 yuan

Zhitong

NPC released its performance for the first three quarters, with a net profit attributable to the parent company of 402 million yuan, a year-on-year decrease of 9.03%

NPC announced that the company has completed the repurchase of 17,999,900 shares, accounting for 1.38% of the total share capital, with an actual repurchase amount of 88.9221 million yuan, and a price range of 4.69 yuan/share to 5.22 yuan/share. This repurchase is intended for the implementation of the 2025 restricted stock incentive plan. The company first disclosed the repurchase plan on March 15, 2025, with an expected repurchase amount between 70 million yuan and 132 million yuan. The funds used for the repurchased shares come from the company's own funds or self-raised funds

NPC: Completed the repurchase of 17,999,900 shares

NPC announced that it will pay the principal and interest of the fourth phase of the ultra-short-term financing bonds for the year 2025. The bond issuance amount is 500 million yuan, with an interest start date of May 22, 2025, and a term of 180 days. The interest rate for this period is 1.54%. The principal and interest payment date is November 18, 2025, with a total amount of 503.7973 million yuan to be repaid. The lead underwriters are Shanghai Pudong Development Bank and Bank of Nanjing

NPC: Will repay the principal and interest of 500 million yuan in ultra-short-term financing bonds

NPC announced that the Nanjing Pharmaceutical convertible bonds will start converting into shares from July 1, 2025. As of September 30, 2025, the cumulative conversion amount is 66,000 yuan, resulting in 12,875 shares, accounting for 0.00098% of the issued shares. As of September 30, 2025, the amount of Nanjing Pharmaceutical convertible bonds that have not yet been converted is 1.081 billion yuan, accounting for 99.9939% of the total issuance

NPC: The cumulative conversion amount of Nanjing Pharmaceutical's convertible bonds is 66,000 yuan

NPC disclosed its share repurchase progress, with the repurchase amount reaching 80.2576 million yuan. The repurchase plan was first announced on March 15, 2025, with an implementation period from March 14, 2025, to March 14, 2026. The expected repurchase amount is between 70 million yuan and 131.58 million yuan, mainly for employee stock ownership plans or equity incentives. As of September 30, 2025, the company has repurchased 16.299951 million shares, accounting for 1.25% of the total share capital

NPC disclosed the progress of its centralized bidding repurchase of shares, having repurchased shares worth 80.2576 million yuan

600332

00874

Guangzhou Baiyunshan Pharmaceutical Group, through its subsidiary Guangyao Phase II Fund, acquired an 11.04% stake in NPC for 749 million yuan. NPC is primarily engaged in pharmaceutical wholesale, retail, and logistics, covering multiple provinces and cities. Baiyunshan stated that this acquisition will optimize its layout in the East China region, enhance competitive advantages, and promote growth in its pharmaceutical manufacturing business. On Monday, Baiyunshan's stock price rose slightly by 0.4%, closing at HKD 18.05

BambooWorks

GYBYS

BAIYUNSHAN PH

Brief News: BAIYUNSHAN PH spent 750 million to acquire a 10% stake in NPC

BAIYUNSHAN PH announced that the Guangzhou Pharmaceutical Phase II Fund will acquire an 11.04% stake in NPC for 748.8 million yuan. The share transfer contract for this transaction will be signed on September 26, 2025. After the acquisition, the Guangzhou Pharmaceutical Phase II Fund will hold an 11.04% stake in NPC. In addition, both parties have signed a strategic investment agreement aimed at strengthening cooperation, including collaboration in capital, supply chain integration, and the field of traditional Chinese medicine. NPC is a pharmaceutical distribution enterprise owned by Nanjing City, primarily engaged in pharmaceutical wholesale, retail, and logistics

BAIYUNSHAN PH: Guangzhou Pharmaceutical's second-phase fund plans to acquire 11.04% equity in NPC for 748.8 million yuan

NPC has signed a strategic investment agreement with BAIYUNSHAN PH and Guangzhou Pharmaceutical Phase II Fund, under which the Guangzhou Pharmaceutical Phase II Fund intends to acquire 145 million shares of NPC, accounting for 11.04% of the total share capital. Both parties will jointly formulate market expansion plans, optimize the supply chain, enhance industrial chain cooperation, promote the transformation and upgrading of the traditional Chinese medicine industry, build a modern circulation system for Chinese medicinal materials, and promote traditional Chinese medicine culture

Nanjing Pharmaceutical: Baiyunshan's subsidiary Guangyao Phase II Fund intends to acquire 145 million shares of the company

According to the Zhitong Finance APP, NPC disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 27.967 billion yuan, a year-on-year increase of 2.70%; net profit attributable to shareholders was 291 million yuan, a year-on-year decrease of 6.44%; net profit excluding non-recurring items was 262 million yuan, a year-on-year decrease of 14.08%; basic earnings per share were 0.222 yuan. The company plans to distribute a cash dividend of 1.70 yuan (including tax) for every 10 shares to all shareholders

NPC released its semi-annual performance report, with a net profit attributable to the parent company of 291 million yuan, a year-on-year decrease of 6.44%

NPGC(600713.SH)